We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Adults with a loss-of-function mutation in the MC4R gene ...

Palatin (PTN) Technologies announced that preclinical data from the Company’s melanocortin 4 receptor, or MC4R, selective PL7737 obesity program will be highlighted in a poster presentation at ...

An impressive large-scale genetic study, led by scientists at the University of Cambridge, has homed in on a number of specific variants in a single gene that can help people either lose or gain ...

Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001). Primary ...

BOSTON, July 12, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ...

Please provide your email address to receive an email when new articles are posted on . Adults with severe obesity due to a melanocortin‐4 receptor deficiency have a longer gastric emptying time and ...

MONTREAL, Nov. 6, 2025 /PRNewswire/ -- Congruence Therapeutics, a computationally-driven biotechnology company building a unique pipeline of pharmacological correctors for diseases of protein ...

Credit: Rhythm Pharmaceuticals The approval for younger patients was based on data from the 1-year, open-label, phase 3 VENTURE trial. Results from the VENTURE trial showed significant reductions in ...

-- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI ...

Plastic structural changes in the melanocortin circuitries that are mediated by melanocortin 4 receptor (MC4R) have been associated with anhedonic behaviours following chronic stress, and there is ...